Regulations and compliance · Practical guide

Investigational medicinal products: linking GMP and GCP data at handover

GMP and GCP meet at specific data exchanges for investigational medicinal products. Manufacturing status, Qualified Person certification, trial authorisation and shipment must match the intended use. Identify the information that manufacturer and sponsor need to connect before a technically successful transfer can support release for use in the trial.

Table of contents

At a glance

Which evidence links GMP manufacture to GCP use of investigational medicinal products?

Link the applicable product and document version to the manufactured batch, QP certification and regulatory release under the sponsor’s responsibility. Include shipment and recipient identity and required storage and transport records. Define responsibilities and information flows. Warehouse status or acknowledgement of receipt does not replace the appropriate certification or verification of required trial authorisations before supply for trial use.

  • Demonstrate separate validation of QP certification and regulatory sponsor release.
  • Unambiguously link product, batch, study, and recipient.
  • Changes and required documentation must both be promptly communicated to both parties.

1. Specifically define the GMP/GCP interface

Source date: 7 October 2026. For the manufacture and import of human investigational medicinal products, the detailed Commission Guideline C(2017) 8179 of 8 December 2017 applies. Complementary to this, the EMA Guideline on Sponsor Responsibility for Handling and Distribution, effective from 1 January 2023, also applies.

The manufacturing guideline expressly excludes investigational advanced therapy medicinal products from its stated scope and points to their specific GMP framework. Assess reconstitution and certain nationally regulated activities separately. The workflow in this article does not cover every clinical product.

The shipping guideline covers the interface between GMP and GCP. It expressly excludes direct deliveries to patients from its scope. Where national law defines such deliveries, the applicable provisions of the guideline should be followed. This article covers controlled supply to trial sites and relevant pharmacies.

Sources: [1] [2]

2. Certification and sponsor release are distinct

The release process includes batch certification by the Qualified Person and subsequent regulatory release by the sponsor for use at trial sites. The EMA guideline describes checking that certification is complete and the necessary trial authorisations are in place.

These steps shall be documented and retained in the Trial Master File. Study investigational products shall remain under the sponsor's control until completion of the release process. Delegation of regulatory release to the manufacturer is possible, but must be accompanied by agreed-upon information and responsibilities.

The distinction does not require two separate software products. It requires that both decision criteria, their scope, and their responsible execution remain clearly identifiable. A shared status "Release" should not obscure this intended meaning.

Sources: [2] [1]

3. Describe the information requirements at each transfer point

The handover matrix links the technical question to the required reference. It is particularly useful when manufacturers, sponsor, and logistics partners use different systems. Not every location requires every confidential information; access is granted based on its specific role.

A technical receipt confirmation serves as a useful traceable record of data flow. It must additionally be demonstrable that the content is correctly assigned and suitable for the subsequent decision.

Work aid for GMP/GCP data transfers
TransferContext neededTypical outstanding question
Sponsor a manufacturer Current relevant product, protocol, and approval status Does a regulatory-significant change reach production in a timely manner?
Manufacturing under QP Batch and required documentation of the Product Specification File Does the assessment relate to the appropriate state?
QP Evidence for Sponsor Process Unique certification of the intended batch Is a technical status update being accepted instead of a decision?
Shipping sponsor process Permissible supply, product identity, and intended recipient Is the release for the correct study constellation available?
Shipment to the trial site Identity, quantity and required transport- and storage conditions Who evaluates deviations and confirms acceptance?

Sources: [1] [2]

4. Maintain the Product Specification File, including all its amendments, in a usable and up-to-date state

The Product Specification File consolidates key reference documents for GMP-compliant manufacturing and clinical trial authorization. It may reference other documents and does not need to be a single file. The Manufacturing Procedure Directive requires continuous updating with traceability to prior versions.

The required components must be available at the manufacturing site. This includes specifications, manufacturing processes, approved labeling, relevant study documentation, agreements, and storage and transport conditions. The scope and content depend on the product and development stage.

For IT this means: It is not sufficient to display only the latest version; the relevant version applicable to a specific process must be clearly identifiable. A subsequently updated reference must not render the previous decision rationale incomprehensible.

Sources: [1] [3]

5. Purposefully identify a incorrect study reference

In the following example, Batch C01 has been certified by the Quality Personnel (QP). The sponsor process is intended to enable supply for study scenario S-A to the inspection site Z-A. For the second scenario S-B, the required authorizations and approval documentation are still pending.

The core of the example is not quantitative calculation, but the scope of the decision. The correct batch alone is insufficient if it is selected for use in a different, yet unapproved study.

Also check the feedback from the shipping process. It must clearly indicate which shipment was dispatched together with relevant identifying information. A general statement of "successfully completed" without specific assignment does not establish an audit trail.

Example: Inspection matrix for the joint review of batch and study usage
ScenarioExisting basisExpected behaviour
C01 for S-A to Z-A QP Certification and required sponsor release are in place Delivery available upon fulfillment of the specified additional conditions.
C01 for S-B QP Certification available, required authorization documents pending No supply for study use solely based on batch status
C02 for S-A Release applies only to C01 Do not silently accept the wrong batch
C01 to a different recipient Shipping order specifies Z-A Investigate recipient deviation prior to execution
Delivery feedback Appropriate product, recipient, and transport information required Do not treat a technical receipt notification as a complete professional acceptance.

Sources: [2] [1]

6. Blinding and transport data do not lose at the system border

The manufacturing procedure contains specific requirements regarding randomization codes, packaging, and documented verification of blinding. Consequently, for data transfers, a carefully defined scope of information is established: a logistics function must not inadvertently receive information that is outside its scope of responsibility and that could compromise blinding.

Simultaneously, the designated responsible personnel must have access to necessary unblinding mechanisms. The EMA guidelines specify this access for the investigational site prior to study initiation or for the availability of corresponding procedures upon receipt of the investigational product. A blanket concealment of all information would therefore be equally inappropriate.

Shipping data must clearly demonstrate product identity, the intended recipient, and the required conditions. Temperature recordings must be retained and evaluated upon delivery. Deviations require a formal assessment of their quality implications; a cleared alarm alone does not constitute such an evaluation.

Sources: [1] [2]

7. Checklist for manufacturers, sponsor, and IT

The checklist serves to discuss a specific data transfer prior to use or modification. It complements separate technical evaluations and does not create a new shared mandatory document for all parties involved.

  • Product and activity scope including special exemptions clarified.
  • The relevant product, document, and approval status is identifiable.
  • QP Certification and regulatory sponsor release to be functionally separated.
  • Batch, study configuration, and intended recipient clearly linked.
  • Delegated responsibilities and necessary information access are formally documented.
  • Required blinding and authorised access for unblinding are addressed.
  • Shipping and transportation information linked to technical assessment.
  • Changes and deviations reach the responsible parties.
  • Storage and subsequent access to data between manufacturer and sponsor have been coordinated.

Sources: [1] [2]

8. Organize the handover so that it functions in daily operations

A small manufacturer should discuss with the sponsor a complete pilot pathway prior to technical implementation: key documentation, certification, regulatory release, shipping, and feedback. This clearly identifies which information is actually exchanged and which party evaluates open items.

Agree the change process as well. Revised labelling, a protocol amendment or a different trial site may have different consequences. Determine the action from the impact and make sure its assessment is available beyond the technical ticketing system.

For storage and access control, the relevant document types and responsibilities are decisive. Manufacturer GMP storage requirements and Trial Master File obligations are not universally equivalent. Agreements must ensure that the sponsor continues to receive required documentation even when different storage purposes are involved.

Sources: [1] [2]

Further reading:

Project experience and collaboration

Trace the transfer of data between manufacturer and sponsor

For a selected investigational medicinal product batch, we trace the document version, QP certification, sponsor decision and shipment information with the responsible people. At handover, we check whether the recipient can unambiguously identify the applicable version. A missing reference may be addressed directly. Conflicting versions require an operational decision first. We support the data flow and evidence structure. Certification and regulatory release remain with those authorised to perform them.

Frequently asked questions about Investigational medicinal products under GMP and GCP

Does QP certification replace sponsor release?

No. The EMA guideline distinguishes between QP certification and subsequent regulatory approval for study use. The completed certification and required study authorizations must be verified. Both steps must be clearly documented and traceable.

Sources: [2]

Can the manufacturer assume regulatory release?

Yes, if the sponsor delegates this task accordingly and provides all necessary information. The agreement must clearly define responsibilities and the procedure. Technical authorization within a system alone does not constitute such a delegation.

Sources: [2] [1]

Must the Product Specification File be a single PDF file?

No. The guideline allows for consolidation or referencing of essential documentation. What is crucial are appropriate content, currency, traceability of previous versions, and required access for the relevant activities.

Sources: [1]

Is the current document version sufficient for all previous batches?

Not automatically. For reconstruction, it must be clearly evident which version of a previous manufacture or decision served as the basis. Continuous updating of the Product Specification File shall preserve traceability to earlier versions.

Sources: [1] [3]

Is every shift in the warehouse already a delivery for study use?

No. Internal or controlled logistical steps are to be evaluated based on their actual purpose. The regulatory release described herein pertains to supply for study use; a warehouse movement status shall not substitute for this decision.

Sources: [2]

Can all involved partners view randomization codes?

Match access to the task and the intended blinding arrangements. Authorised staff need access to required information, particularly to carry out planned unblinding. This does not justify either universal access for all partners or concealing all information from every party.

Sources: [1] [2]

What does the receipt confirmation of an interface demonstrate?

It can demonstrate successful transmission. It does not establish that the destination contains the correct batch, study context and basis for the decision. Specify the required data and acknowledgement as well as the technical status.

Sources: [1] [2]

What is the significance of transport deviations for data transfer?

The required records must be assignable to the specific product and shipment and must be capable of being professionally evaluated. The EMA guidelines require a formal assessment of quality implications when deviations from shipping conditions occur. A simple alarm clearance does not substitute for this evaluation.

Sources: [2]

Do these rules apply unchanged to investigational advanced therapy medicinal products?

No. The detailed manufacturing protocol explicitly excludes investigational therapeutics from its scope and refers to specific GMP requirements. Please verify the appropriate product area before transferring any requirements or procedures.

Sources: [1]

Must manufacturers and sponsors retain all documentation for the same period of time?

Document types and responsibilities have different retention requirements. In particular, clarify the sponsor's access to documents required for the Trial Master File. A common technical platform does not eliminate these differences.

Sources: [1] [2]

Sources and review date

Source date: 7 October 2026. Manufacturing/import and controlled supply of human investigational preparations to clinical trial sites within the described EU scope. ATMPs, reconstitution, and direct patient delivery involve specific distinctions. No blanket equivalence between GMP and GCP. Tables and case examples are intended as standalone reference tools, not as results of completed product testing. Draft versions do not establish enforceable additional obligations.

  1. European Commission: GMP guideline for investigational medicinal products8 December 2017, C(2017)8179, applicable with the Clinical Trials Regulation. Section 1 sets the scope. Sections 2.1, 5–5.5 and 7–8 cover the product specification file, changes, packaging and blinding, and certification. Section 8, lines 508–513, addresses delegation of regulatory release.
  2. EMA and European Commission: sponsor responsibilities for handling and shipping investigational medicinal productsEMA/INS/GMP/258937/2022; published on 14 September 2022, effective from 1 January 2023; Sections 1–4, in particular Section 2, paragraphs 2–5 and Section 4, unblinding; Section 3, shipping data/temperature assessment; Section 4, responsibilities and storage access
  3. European Commission: EU GMP Chapter 4, DocumentationJanuary 2011, in force from 30 June 2011. Sections 4.1–4.5 and 4.8–4.10 concern links, current documents and traceable records. Section 5 of the guidance for investigational medicinal products refers to these provisions.

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Design traceable GMP and GCP transfers

We assist you in describing the required data links, responsibilities, and review cases between manufacturing and study supply. The respective decisions of the Quality Personnel (QP) and Sponsor remain clearly distinct.

  • Computer system validation →

    Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

Send a project enquiry Customer testimonials →